Targeting Reduced BDNF/TrkB-Mediated Neuroplasticity in Brain Disorders

PI: Etienne Sibille (CAMH, UofT), Mark Reed (Krembil Institute, UHN)

Co-I: Francis Lee (Weill Cornell Medical College), Toshi Tomoda (CAMH, UofT)

On June 15th, 2023, we are awarded this Krembil Foundation grant for screening and characterizing novel compounds that could facilitate neuroplasticity through BDNF/TrkB pathway.

Lay Summary: Neuroplasticity, the capacity of the brain to respond and adapt to the environment, is reduced in depression, aging, and age-related disorders, including Alzheimer’s disease. Reduced neuroplasticity contributes to the cognitive symptoms that are central to these disorders. There are currently no drugs that restore neuroplasticity, mostly due to difficulties in targeting the underlying brain pathways. We propose here an innovative approach to identify novel molecules that augment neuroplasticity. Results will lead to much-needed tools for innovative research on neuroplasticity and advance the development of novel therapeutics for the unmet need of cognitive deficits across brain disorders, including Alzheimer’s disease.